Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of the listed cancer types (like ovarian, lung, or colorectal cancer) that has spread or cannot be removed by surgery.
- Your cancer has gotten worse during or after standard treatment, or you cannot tolerate that treatment, or you have chosen not to have standard treatment. You must have had at least one prior chemotherapy or similar therapy.
- You have at least one tumor that can be measured on scans.
- Your doctor expects you to live for at least 12 more weeks.
- You are not pregnant or breastfeeding, and you do not have an active uncontrolled infection or certain viral infections (HIV, hepatitis B or C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This study tests an experimental drug called EP0089 for people with advanced solid tumors that haven't responded to other treatments. It aims to find a safe dose and see if it helps control the cancer.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.